By contrast, the suppression of SETD5 expression leads to reduced cell growth and migration in pancreatic cancer, prostate cancer, and hepatocellular carcinoma (HCC) (13, 34, 58), as well as enhanced resistance to chemotherapeutic drugs (13). The gene discussed is SETD5; the disease is prostate carcinoma.